Galapagos and Gilead Strengthen Collaboration on Innovative Autoimmune Therapies

Galapagos and Gilead Sciences have entered into a binding framework agreement to collaborate on a T cell engager program targeting autoimmune diseases. The partnership follows Gilead's acquisition of Ouro Medicines, the developer of the clinical-stage candidate Gamgertamig (OM336). Under the revised terms, Galapagos will benefit from improved financial flexibility and will retain a significant portion of its cash reserves for other strategic transactions. The collaboration aims to advance a potential first-in-class treatment, strengthening the competitive position of both companies in the biotech sector. This strategic move optimizes capital allocation for Galapagos while allowing Gilead to leverage its recent acquisition to bolster its autoimmune pipeline. The agreement underscores a shared commitment to accelerating clinical development while maintaining a disciplined approach to financial management.